TC Biopharm (Holdings) Plc (TCBWF)

Market Cap	557.31K
Revenue (ttm)	n/a
Net Income (ttm)	-15.22M
Shares Out	n/a
EPS (ttm)	-161.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000
Average Volume	15,375
Open	0.0037
Previous Close	n/a
Day's Range	0.0037 - 0.0050
52-Week Range	0.0011 - 0.0390
Beta	n/a
RSI	52.74
Earnings Date	Aug 21, 2025

About TC Biopharm (Holdings)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 39
• Stock Exchange: OTCMKTS
• Ticker Symbol: TCBWF